[Angioimmunoblastic lymphadenopathy with dysproteinemia: personal experience with 3 cases and review of the literature].
OBJECTIVE
We report personal experience on 3 cases of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). We stress the prognostic and therapeutic aspects of this rare disease, that remain still unclear in recent literature.


METHODS
We performed a retrospective study on 3 cases of AILD, with a mean follow-up of 32.6 months (range 30-36).


METHODS
Internal Medicine Unit.


METHODS
We observed three patients, 2 males and 1 female, with a mean age of 65 years (range 51-72), with AILD confirmed by histopathological exams and evidence of unfavorable prognostic features at the time of diagnosis.


METHODS
2 patients received polychemotherapy with cyclophosphamide+prednisone; cyclophosphamide + vincristine + prednisone. One patient was treated with low doses of prednisone (25 mg/day).


METHODS
We evaluated the degree of response (absent, partial, complete) an the time of survival (< 18 months or > 24 months).


RESULTS
Response to therapy was partial in all patients; 1 patient underwent a severe bone marrow depression. All patients were alive for more than 24 months.


CONCLUSIONS
The clinical course was independent of therapy (intensive or symptomatic) and prognostic criteria in all 3 patients. At present AILD is considered as a potentially malignant disease. Polychemotherapy must be used as a first choice treatment.
Di Natale
M
M
Unità Operativa di Medicina Interna I, Ospedale di Prato, Firenze.
Biagioni
P
P
Fiusti
R
R
Grassi
M
M
Santini
M
M
Corradi
F
F
D001796:Blood Protein Disorders / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
Linfoadenopatia angioimmunoblastica con disprotidemia: esperienza personale su tre casi e revisione della letteratura.